LOS ANGELES, March 27 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Inovio Biomedical Corporation . Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. Ross Silver of Vista Partners issued the report. For more information and to download the report, please visit the Vista Partners website at www.vistap.com.
Inovio Biomedical is focused on commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy and development of multiple DNA vaccines using its delivery platform for gene-based treatments. SECTA is a local ablation therapy for solid tumors designed, as an alternative to surgery, to selectively kill cancerous cells and minimize cosmetic or functional impacts to predominantly healthy tissue typically treated around a tumor. Inovio is moving its lead product, the MedPulser(R), through pre- marketing studies for head & neck and skin cancers in Europe, where it has CE Mark accreditation, a U.S. phase III pivotal study for head and neck cancer, and a phase I/II trial for breast cancer. Inovio’s DNA delivery partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four DNA vaccines and immunotherapies in phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation, which uses brief, controlled electrical pulses to dramatically increase both cellular uptake of a useful biopharmaceutical and, in the case of gene-based treatments, levels of gene expression. Inovio has the most extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.
Contact: Vista Partners LLC Ross Silver, Jeremy Thum (415) 738-6229 info@vistap.comwww.vistap.com
Vista Partners LLC
CONTACT: Ross Silver, Jeremy Thum, both of Vista Partners LLC,+1-415-738-6229, or info@vistap.com
